| An analysis demonstrating the ability of DX-88 to resolve symptoms of acute hereditary angioedema attacks in all anatomic locations and to sustain effect will be presented in an oral presentation this week at the American College of Allergy, Asthma and Immunology 2009 Annual Meeting in Miami Beach. This evaluation, and two others to be presented, highlight efficacy and safety analyses from the integrated analysis of the two Phase 3 placebo-controlled trials, EDEMA3 and EDEMA4, of DX-88, the lead product candidate of Dyax Corp , for the treatment of acute attacks of HAE. :theflyonthewall.com |
